class,DDI 0,The excretion of drug_a can be decreased when combined with drug_b. 1,The excretion of drug_a can be increased when combined with drug_b. 2,The excretion of drug_b can be decreased when combined with drug_a. 3,The metabolism of drug_a can be decreased when combined with drug_b. 4,The metabolism of drug_a can be increased when combined with drug_b. 5,The metabolism of drug_b can be decreased when combined with drug_a. 6,The metabolism of drug_b can be increased when combined with drug_a. 7,The protein binding of drug_a can be decreased when combined with drug_b. 8,The risk or severity of Cardiac Arrhythmia can be increased when drug_b is combined with drug_a. 9,The risk or severity of adverse effects can be increased when drug_a is combined with drug_b. 10,The risk or severity of adverse effects can be increased when drug_b is combined with drug_a. 11,The risk or severity of angioedema can be increased when drug_a is combined with drug_b. 12,The risk or severity of angioedema can be increased when drug_b is combined with drug_a. 13,The risk or severity of bleeding can be increased when drug_a is combined with drug_b. 14,The risk or severity of hyperglycemia can be increased when drug_b is combined with drug_a. 15,The risk or severity of hyperkalemia can be increased when drug_a is combined with drug_b. 16,The risk or severity of hyperkalemia can be increased when drug_b is combined with drug_a. 17,The risk or severity of hypoglycemia can be increased when drug_a is combined with drug_b. 18,The risk or severity of hypoglycemia can be increased when drug_b is combined with drug_a. 19,The risk or severity of hypotension and orthostatic hypotension can be increased when drug_a is combined with drug_b. 20,The risk or severity of hypotension can be increased when drug_a is combined with drug_b. 21,The risk or severity of hypotension can be increased when drug_b is combined with drug_a. 22,"The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when drug_a is combined with drug_b." 23,The risk or severity of lactic acidosis can be increased when drug_b is combined with drug_a. 24,The risk or severity of liver damage can be increased when drug_a is combined with drug_b. 25,The risk or severity of myopathy and rhabdomyolysis can be increased when drug_b is combined with drug_a. 26,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug_a is combined with drug_b." 27,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug_b is combined with drug_a." 28,The risk or severity of neutropenia can be increased when drug_a is combined with drug_b. 29,The risk or severity of orthostatic hypotension and syncope can be increased when drug_a is combined with drug_b. 30,"The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when drug_a is combined with drug_b." 31,The risk or severity of rhabdomyolysis can be increased when drug_b is combined with drug_a. 32,The risk or severity of thrombocytopenia can be increased when drug_a is combined with drug_b. 33,The risk or severity of weight gain and edema formation can be increased when drug_b is combined with drug_a. 34,The serum concentration of drug_a can be decreased when it is combined with drug_b. 35,The serum concentration of drug_a can be increased when it is combined with drug_b. 36,The serum concentration of drug_b can be decreased when it is combined with drug_a. 37,The serum concentration of drug_b can be increased when it is combined with drug_a. 38,The therapeutic efficacy of drug_a can be decreased when used in combination with drug_b. 39,The therapeutic efficacy of drug_a can be increased when used in combination with drug_b. 40,The therapeutic efficacy of drug_b can be increased when used in combination with drug_a. 41,drug_a may decrease the excretion rate of drug_b which could result in a higher serum level. 42,drug_a may increase the QTc-prolonging activities of drug_b. 43,drug_a may increase the anticoagulant activities of drug_b. 44,drug_a may increase the diuretic activities of drug_b. 45,drug_a may increase the excretion rate of drug_b which could result in a lower serum level and potentially a reduction in efficacy. 46,drug_a may increase the hepatotoxic activities of drug_b. 47,drug_a may increase the hypoglycemic activities of drug_b. 48,drug_a may increase the hypolipidaemic activities of drug_b. 49,drug_a may increase the hypotensive activities of drug_b. 50,drug_a may increase the vasodilatory activities of drug_b. 51,drug_b may decrease the excretion rate of drug_a which could result in a higher serum level. 52,drug_b may decrease the hypoglycemic activities of drug_a. 53,drug_b may increase the diuretic activities of drug_a. 54,drug_b may increase the excretion rate of drug_a which could result in a lower serum level and potentially a reduction in efficacy. 55,drug_b may increase the hypoglycemic activities of drug_a. 56,drug_b may increase the hypolipidaemic activities of drug_a. 57,drug_b may increase the hypotensive activities of drug_a. 58,drug_b may increase the myopathic rhabdomyolysis activities of drug_a. 59,drug_b may increase the orthostatic hypotensive activities of drug_a.